Abstract
Cancer is a multifactorial disease including interactions of complex genetic and environmental factors. Clinical efficacy of anticancer chemotherapies is hampered by various factors including multidrug resistance (MDR). There is a strong need to discover more potent novel cancer drugs to kill cancer cells selectively. The recent new strategy for cancer treatment involves the design and synthesis of hybrid compounds as multitargeted anticancer agents. In this review, we focus on studies using hybrid compounds which were designed and synthesized from two or more different bioactive moieties conjugating them into a single hybrid drug. Hybrid compounds having more than a single target have been considered as more efficient and potent anticancer agents, since it is almost impossible to destroy cancer cells with a single target. Hybrid compounds overcome many disadvantages of single cancer drugs such as low solubility, adverse effects, and multi drug resistance. We have compiled the data of recent studies using the new hybrid anticancer drugs in cancer treatment. Thus, the design, synthesis and clinical trials of new hybrid compounds should be continued and supported in future. Results of recent studies have proved that they have a great potential to be used as novel anticancer drugs.
Keywords: Hybrid Compounds, Cancer, Anticancer Agents, Multitarget Compounds, Drug Design, Natural Products.
Current Topics in Medicinal Chemistry
Title:Hybrid Compounds as Multitarget Directed Anticancer Agents
Volume: 17 Issue: 8
Author(s): Ertan Kucuksayan and Tomris Ozben
Affiliation:
Keywords: Hybrid Compounds, Cancer, Anticancer Agents, Multitarget Compounds, Drug Design, Natural Products.
Abstract: Cancer is a multifactorial disease including interactions of complex genetic and environmental factors. Clinical efficacy of anticancer chemotherapies is hampered by various factors including multidrug resistance (MDR). There is a strong need to discover more potent novel cancer drugs to kill cancer cells selectively. The recent new strategy for cancer treatment involves the design and synthesis of hybrid compounds as multitargeted anticancer agents. In this review, we focus on studies using hybrid compounds which were designed and synthesized from two or more different bioactive moieties conjugating them into a single hybrid drug. Hybrid compounds having more than a single target have been considered as more efficient and potent anticancer agents, since it is almost impossible to destroy cancer cells with a single target. Hybrid compounds overcome many disadvantages of single cancer drugs such as low solubility, adverse effects, and multi drug resistance. We have compiled the data of recent studies using the new hybrid anticancer drugs in cancer treatment. Thus, the design, synthesis and clinical trials of new hybrid compounds should be continued and supported in future. Results of recent studies have proved that they have a great potential to be used as novel anticancer drugs.
Export Options
About this article
Cite this article as:
Kucuksayan Ertan and Ozben Tomris, Hybrid Compounds as Multitarget Directed Anticancer Agents, Current Topics in Medicinal Chemistry 2017; 17 (8) . https://dx.doi.org/10.2174/1568026616666160927155515
DOI https://dx.doi.org/10.2174/1568026616666160927155515 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Withdrawal Notice: TP53 Targetome: A Database of Novel Breast Cancer Biomarkers
Current Drug Targets Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies Across Caco-2 Cells
Current Drug Delivery Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Implications of Metal Nanoparticles on Aquatic Fauna: A Review
Nanoscience & Nanotechnology-Asia Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Platelet Toll-Like Receptor Expression: The Link Between “Danger” Ligands and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology Understanding Apoptosis in Terms of QSAR
Anti-Cancer Agents in Medicinal Chemistry Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Use of Anti-Infective Drugs in Rheumatology
Anti-Infective Agents in Medicinal Chemistry Linear Peptides in Intracellular Applications
Current Medicinal Chemistry Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
Anti-Cancer Agents in Medicinal Chemistry Methods for the Aesthetic Evaluation of Breast Cancer Conservation Treatment: A Technological Review
Current Medical Imaging The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives
Anti-Cancer Agents in Medicinal Chemistry